<DOC>
	<DOC>NCT01778101</DOC>
	<brief_summary>This study is pilot study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux documented by 24hr pH impedance monitoring</brief_summary>
	<brief_title>Lansoprazole in Preterm Infants With Reflux</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>preterm infant documented gastrointestinal reflux by 24hr pH monitoring unstable vital sings congenital anomaly in upper gastrointestinal tract incuding esophagus drug history of H2 blocker during last 1 week medication of warfarin, carbamazepine, phenytoin, rifampin renal or hepatic dysfunction inappropriate clinical conditions judged by researchers</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>preterm infants</keyword>
	<keyword>reflux</keyword>
	<keyword>impedance</keyword>
	<keyword>pH</keyword>
	<keyword>monitoring</keyword>
	<keyword>lansoprazole</keyword>
</DOC>